UBS has upgraded Centene Corporation's shares from Neutral to Buy, raising the price target to $80.00, citing the stock's undervaluation despite potential challenges ahead. The healthcare provider's strong financial health and growth strategies in Medicaid and Medicare are expected to drive earnings, with a projected EPS of $8.00 in 2026. Centene's current trading position near its 52-week low and a P/E ratio of 10x suggest significant upside potential, as UBS believes market expectations for 2026 EPS are overly pessimistic.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
